Kazia Therapeutics Ltd ADR (KZIA) - Total Assets
Based on the latest financial reports, Kazia Therapeutics Ltd ADR (KZIA) holds total assets worth $6.06 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Kazia Therapeutics Ltd ADR investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Kazia Therapeutics Ltd ADR - Total Assets Trend (1999–2025)
This chart illustrates how Kazia Therapeutics Ltd ADR's total assets have evolved over time, based on quarterly financial data. Explore KZIA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Kazia Therapeutics Ltd ADR - Asset Composition Analysis
Current Asset Composition (June 2025)
Kazia Therapeutics Ltd ADR's total assets of $6.06 Million consist of 81.4% current assets and 18.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 71.7% |
| Accounts Receivable | $90.00K | 1.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.09 Million | 17.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Kazia Therapeutics Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KZIA market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kazia Therapeutics Ltd ADR's current assets represent 81.4% of total assets in 2025, an increase from 78.3% in 1999.
- Cash Position: Cash and equivalents constituted 71.7% of total assets in 2025, up from 52.8% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is intangible assets at 17.9% of total assets.
Kazia Therapeutics Ltd ADR Competitors by Total Assets
Key competitors of Kazia Therapeutics Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Kazia Therapeutics Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.35 | 0.24 | 2.10 |
| Quick Ratio | 0.35 | 0.24 | 2.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-9.12 Million | $-19.65 Million | $5.59 Million |
Kazia Therapeutics Ltd ADR - Advanced Valuation Insights
This section examines the relationship between Kazia Therapeutics Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.09 |
| Latest Market Cap to Assets Ratio | 10.70 |
| Asset Growth Rate (YoY) | -71.9% |
| Total Assets | $6.06 Million |
| Market Capitalization | $64.84 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Kazia Therapeutics Ltd ADR's assets at a significant premium (10.70x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Kazia Therapeutics Ltd ADR's assets decreased by 71.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kazia Therapeutics Ltd ADR (1999–2025)
The table below shows the annual total assets of Kazia Therapeutics Ltd ADR from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $6.06 Million | -71.92% |
| 2024-06-30 | $21.59 Million | -23.14% |
| 2023-06-30 | $28.08 Million | -21.75% |
| 2022-06-30 | $35.89 Million | -38.22% |
| 2021-06-30 | $58.09 Million | +151.86% |
| 2020-06-30 | $23.06 Million | +8.91% |
| 2019-06-30 | $21.18 Million | -24.84% |
| 2018-06-30 | $28.18 Million | -21.54% |
| 2017-06-30 | $35.91 Million | +1.11% |
| 2016-06-30 | $35.52 Million | -23.02% |
| 2015-06-30 | $46.14 Million | +890.31% |
| 2014-06-30 | $4.66 Million | -48.15% |
| 2013-06-30 | $8.98 Million | 0.00% |
| 2012-06-30 | $8.98 Million | -29.40% |
| 2011-06-30 | $12.73 Million | -34.02% |
| 2010-06-30 | $19.29 Million | -49.02% |
| 2009-06-30 | $37.84 Million | -12.76% |
| 2008-06-30 | $43.38 Million | -15.64% |
| 2007-06-30 | $51.42 Million | +0.59% |
| 2006-06-30 | $51.11 Million | -23.95% |
| 2005-06-30 | $67.21 Million | -12.65% |
| 2004-06-30 | $76.94 Million | +51.99% |
| 2003-06-30 | $50.62 Million | -18.26% |
| 2002-06-30 | $61.93 Million | -48.36% |
| 2001-06-30 | $119.94 Million | +84.46% |
| 2000-06-30 | $65.02 Million | +16.37% |
| 1999-06-30 | $55.88 Million | -- |
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase I… Read more